CV3988 inhibits in vivo platelet aggregation induced by PAF-acether and collagen

Eur J Pharmacol. 1986 Apr 9;123(1):91-7. doi: 10.1016/0014-2999(86)90692-8.


Platelet activating factor (PAF-acether) was shown to cause a fall in the circulating platelet count and blood pressure (BP) in anaesthetised rabbits. CV3988 caused a dose-dependent inhibition of these responses to a low dose of PAF-acether (150 ng X kg-1). CV3988 itself was found to cause a fall in both BP and platelet count in vivo. Collagen (40 micrograms X kg-1) i.v. caused sudden death in rabbits and pretreatment with CV3988 (5 mg X kg-1) caused a 62% inhibition of the platelet count response to collagen without significantly increasing the survival rate. In the rat, collagen (40 micrograms X kg-1) was not lethal and CV3988 caused a dose-dependent inhibition of the fall in platelet count due to collagen, but this action was short-lived. CV3988 also caused agonist actions in the rat. These results show that CV3988 inhibits the effects of PAF-acether in vivo and suggests that PAF-acether may play a role in mediating collagen-induced platelet aggregation in vivo.

MeSH terms

  • Animals
  • Blood Pressure / drug effects
  • Collagen / antagonists & inhibitors*
  • Male
  • Phospholipid Ethers*
  • Platelet Activating Factor / physiology*
  • Platelet Aggregation / drug effects*
  • Platelet Count
  • Rabbits
  • Rats
  • Species Specificity
  • Thiazoles / pharmacology*
  • Thromboxane B2 / blood
  • Time Factors


  • Phospholipid Ethers
  • Platelet Activating Factor
  • Thiazoles
  • Thromboxane B2
  • CV 3988
  • Collagen